{"disease":{"id":"anti-neutrophil-cytoplasmic-antibody-associated-vasculitis","name":"anti neutrophil cytoplasmic antibody associated vasculitis"},"drugs":{"marketed":[{"drug_id":"avacopan","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"AVACOPAN","company_name":"Chemocentryx","drug_phase":"marketed","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist [EPC]","quality_score":62,"revenue":"400","mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response."},{"drug_id":"ccx168","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"CCX168","company_name":"Chemocentryx","drug_phase":"discontinued","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist","quality_score":null,"revenue":null,"mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06072482","title":"A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06308978","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT05969522","title":"Stratified Therapy on Pediatric AAGN","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Wang Mo","has_results":false},{"nct_id":"NCT05988008","title":"A Study of CCX168 in Japanese and Caucasian Healthy Adult Males","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04413149","title":"Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":true},{"nct_id":"NCT06350110","title":"Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT07160608","title":"Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05732402","title":"An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Alpine Immune Sciences, Inc.","has_results":false},{"nct_id":"NCT07246096","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06004947","title":"A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07212322","title":"A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06056921","title":"Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05702983","title":"The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07236762","title":"An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07236801","title":"Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07104721","title":"A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07123519","title":"A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05988021","title":"A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06978647","title":"A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07388277","title":"CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":false},{"nct_id":"NCT07490275","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06004960","title":"A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06379646","title":"An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06196905","title":"An Exploratory Study of MT-2990 in Patients With AAV","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Tanabe Pharma Corporation","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}